The illumigene C. difficile assay detects the presence of the toxin-producing region from the bacterium and provides highly accurate results in under an hour, according to Meridian.
The company expects net sales for its 2011 fiscal year to be in the range of $165 million to $170 million, representing an increase of between 14 percent and 17 percent over projected fiscal 2010 sales.
FDA's approval and the subsequent launch in the US of its C. difficile test, along with its purchase of Bioline, marks Meridian's entry into the molecular diagnostic and molecular biology markets.
Meridian Bioscience's acquisition of Bioline both provides Meridian a foothold in the PCR market and is expected to help drive future diagnostic development at the company.
Meridian has acquired the reagents maker, adding complementary products to its life science business. The firm also reported an 11 percent decline in Q3 revenues.
The illumigene C. difficile molecular amplification test is Meridian's first molecular diagnostic product.
Meridian Bioscience's Illumigene C. difficile test; Nanosphere's Verigene SP respiratory virus panel; Veredus Laboratories' VereFlu test and VereID Biosystem; and IMDx's 2009 influenza H1N1 assay
The C. difficile test is the first molecular diagnostic product for Meridian. It hopes to market the test later this year.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.